Intelligent Biosynthetic Nanobiomaterials (IBNs) for Hyperthermic Gene Delivery

Chen, Tze-Haw Howard; Bae, Younsoo; Furgeson, Darin Y.

doi:10.1007/s11095-007-9382-5

Cited by 78 publications

(73 citation statements)

References 43 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although positively charged ELPs have been created by inclusion of cationic guest residues [63, 64], this low charge density was not ideal for DNA condensation as compared to the high charge density provided by contiguous cationic residues. ELPs for DNA condensation have thus been specifically designed as a genetic fusion of an ELP and a cationic domain consisting of an eight-residue oligolysine peptide [54]. This cationic ELP successfully condensed plasmid DNA into particles approximately 32–115 nm in radius, depending on the N/P ratio (the ratio of cationic amine groups contributed by the ELP to anionic phosphate groups contributed by the DNA).…”

Section: Architectures and Assemblies Of Elp Drug Carriersmentioning

confidence: 99%

Applications of elastin-like polypeptides in drug delivery

MacEwan

Chilkoti

2014

Journal of Controlled Release

211

236

View full text Add to dashboard Cite

Elastin-like polypeptides (ELPs) are biopolymers inspired by human elastin. Their lower critical solution temperature phase transition behavior and biocompatibility make them useful materials for stimulus-responsive applications in biological environments. Due to their genetically encoded design and recombinant synthesis, the sequence and size of ELPs can be exactly defined. These design parameters control the structure and function of the ELP with a precision that is unmatched by synthetic polymers. Due to these attributes, ELPs have been used extensively for drug delivery in a variety of different embodiments—as soluble macromolecular carriers, self-assembled nanoparticles, cross-linked microparticles, or thermally coacervated depots. These ELP systems have been used to deliver biologic therapeutics, radionuclides, and small molecule drugs to a variety of anatomical sites for the treatment of diseases including cancer, type 2 diabetes, osteoarthritis, and neuroinflammation.

show abstract

Section: Architectures and Assemblies Of Elp Drug Carriersmentioning

confidence: 99%

Applications of elastin-like polypeptides in drug delivery

MacEwan

Chilkoti

2014

Journal of Controlled Release

211

236

View full text Add to dashboard Cite

show abstract

“…Bi-functional RCPs were also synthesized on a cationic oligomer block fused to an ELP, but in the absence of an endosmal escape mechanism the system lead to poor efficiency. [131] Tri-functional biopolymers were then synthesized in an attempt to achieve efficient gene transfer from RCPs. These polymers consisted of lysine-histidine (K-H) residues with a fibroblast growth factor 2 (FGF2) fusion.…”

Section: Recombinant Cationic Polymersmentioning

confidence: 99%

Controlled release from recombinant polymers

Price

Poursaid

Ghandehari

2014

Journal of Controlled Release

View full text Add to dashboard Cite

Recombinant polymers provide a high degree of molecular definition for correlating structure with function in controlled release. The wide array of amino acids available as building blocks for these materials lend many advantages including biorecognition, biodegradability, potential biocompatibility, and control over mechanical properties among other attributes. Genetic engineering and DNA manipulation techniques enable the optimization of structure for precise control over spatial and temporal release. Unlike the majority of chemical synthetic strategies used, recombinant DNA technology has allowed for the production of monodisperse polymers with specifically defined sequences. Several classes of recombinant polymers have been used for controlled drug delivery. These include, but are not limited to, elastin-like, silk-like, and silk-elastinlike proteins, as well as emerging cationic polymers for gene delivery. In this article, progress and prospects of recombinant polymers used in controlled release will be reviewed.

show abstract

“…Thus, polymers are considered the most receptive for facile modification with various substituents or by block copolymerization. For example, it has been revealed that the feasibility of nanoparticles vectors that optimal polymer compositions such as molecular weight and pKa can be selected plays a pivotal role in facilitating the release and endosomal escape of pDNA and eventually induces high transfection efficiency [36]. In addition, various shapes of nanoparticles can be achieved by varying the polylysine (PLL) counterion present at the time of compaction [37].…”

Section: Variable Physicochemical Properties For Gene Loadingmentioning

confidence: 99%

Nanoparticles for Gene Delivery: A Brief Patent Review

Xu¹,

Zhang

2009

DDF

View full text Add to dashboard Cite

Gene therapy, as therapeutic treatment to genetic or acquired diseases, is attracting much interest in the research community, leading to noteworthy developments over the past two decades. Nonviral vectors have recently received an increasing attention in order to overcome the safety problems of viral counterpart. Nanoparticles with their special characteristics such as small particle size, large surface area and the capability of changing their surface properties have numerous advantages compared with other gene delivery systems. This article reviews the advances of nanoparticles in patents for gene delivery and emphasizes methods to promote gene transfection efficiency.

show abstract

Intelligent Biosynthetic Nanobiomaterials (IBNs) for Hyperthermic Gene Delivery

Cited by 78 publications

References 43 publications

Applications of elastin-like polypeptides in drug delivery

Applications of elastin-like polypeptides in drug delivery

Controlled release from recombinant polymers

Nanoparticles for Gene Delivery: A Brief Patent Review

Contact Info

Product

Resources

About